




Second edition 2024 in Fréjus



# MOFA: Multi-omic Factor Analysis

Jimmy Vandel (PLBS - Bilille)  
Arnaud Gloaguen (CNRGH-CEA)  
Vincent Guillemot (Institut Pasteur)

DOI version final

Method | 20 June 2018 |  OPEN ACCESS

 TRANSPARENT PROCESS

## Multi-Omics Factor Analysis—a framework for unsupervised integration of multi-omics data sets



Ricard Argelaguet , Britta Velten , Damien Arno , Sascha Dietrich , Thorsten Zenz , John C Marioni , Florian Buettner  ✉, Wolfgang Huber  ✉, Oliver Stegle  ✉

### [Author Information](#)

Molecular Systems Biology (2018) 14: e8124 | <https://doi.org/10.15252/msb.20178124>


Method | [Open access](#) | [Published: 11 May 2020](#)

## MOFA+: a statistical framework for comprehensive integration of multi-modal single-cell data

Ricard Argelaguet , Damien Arno, Danila Bredikhin, Yonatan Deloro, Britta Velten, John C. Marioni  & Oliver Stegle 

*Genome Biology* **21**, Article number: 111 (2020) | [Cite this article](#)

44k Accesses | 237 Citations | 118 Altmetric | [Metrics](#)



[About the cover](#)

Volume 14  
Issue 6  
1 June 2018

[IN THIS ISSUE](#)

# Matrix multiplication, back to school



$$\begin{bmatrix} 1 & 2 & 3 \\ 4 & 5 & 6 \end{bmatrix} \times \begin{bmatrix} 10 & 11 \\ 20 & 21 \\ 30 & 31 \end{bmatrix} \\
 = \begin{bmatrix} 1 \times 10 + 2 \times 20 + 3 \times 30 & 1 \times 11 + 2 \times 21 + 3 \times 31 \\ 4 \times 10 + 5 \times 20 + 6 \times 30 & 4 \times 11 + 5 \times 21 + 6 \times 31 \end{bmatrix} \\
 = \begin{bmatrix} 10+40+90 & 11+42+93 \\ 40+100+180 & 44+105+186 \end{bmatrix} = \begin{bmatrix} 140 & 146 \\ 320 & 335 \end{bmatrix}$$


$$c_{11} = a_{11}b_{11} + a_{12}b_{21} + a_{13}b_{31} + a_{14}b_{41}$$

$$\begin{bmatrix} a_{11} & a_{12} & a_{13} & a_{14} \\ a_{21} & a_{22} & a_{23} & a_{24} \end{bmatrix} \begin{bmatrix} b_{11} & b_{12} & b_{13} \\ b_{21} & b_{22} & b_{23} \\ b_{31} & b_{32} & b_{33} \\ b_{41} & b_{42} & b_{43} \end{bmatrix} = \begin{bmatrix} c_{11} & c_{12} & c_{13} \\ c_{21} & c_{22} & c_{23} \end{bmatrix}$$

Matrix dimensions : **2 x 4**                      **4 x 3**                      **2 x 3**

$$c_{22} = a_{21}b_{12} + a_{22}b_{22} + a_{23}b_{32} + a_{24}b_{42}$$

$$\begin{bmatrix} a_{11} & a_{12} & a_{13} & a_{14} \\ a_{21} & a_{22} & a_{23} & a_{24} \end{bmatrix} \begin{bmatrix} b_{11} & b_{12} & b_{13} \\ b_{21} & b_{22} & b_{23} \\ b_{31} & b_{32} & b_{33} \\ b_{41} & b_{42} & b_{43} \end{bmatrix} = \begin{bmatrix} c_{11} & c_{12} & c_{13} \\ c_{21} & c_{22} & c_{23} \end{bmatrix}$$




→ approximate the large data matrix  $A$  using the product of 2 smaller matrices  $W$  and  $H$

$$A = W \times H + \epsilon$$





Useful for dimensionality reduction (k features in the W matrix) and feature extraction (the H matrix)

Example: image processing with Non-Negative Matrix Factorization ( $W \geq 0$  and  $H \geq 0$ )





→ PCA can be formulated as an approximation of matrix factorization

# Matrix factorization, PCA



# Matrix factorization, PCA






$$Y^m = ZW^mT + \epsilon^m$$

- $m$  views / omic sources
- share the  $Z$  matrix between views
- 2 levels of sparsity on  $W^m$  :
  - view and factor-wise  
→ active/inactive factors in a view
  - feature-wise  
→ sparse biological phenomenon
- $Y^m$  and  $\epsilon^m$  can follow different models :
  - Gaussian (continuous)
  - Poisson (natural/count)
  - Bernoulli (binary)








- Automatic Relevance Determination prior
  - view and factor-wise prior following Bernoulli distribution
  - > all factors are not active in each view (view-specific biological phenomenon)



- Spike-and-slab sparsity prior
  - feature-wise prior in each view  $m$  for a given factor  $k$  following 'normal' distribution
  - > small number of features with active weights (sparse biological phenomenon)



$$W = S\widehat{W}, \text{ where } s_{dk}^m \sim \text{Ber}(\theta_k^m) \text{ and } \widehat{W}_{dk}^m \sim N(0, 1/\alpha_k^m).$$



$$\mathbf{Y}^m = \mathbf{Z}\mathbf{W}^m\mathbf{T} + \boldsymbol{\epsilon}^m$$

- Parameter estimation through variational Bayesian inference

$$\begin{aligned}
 p(\mathbf{Y}, \hat{\mathbf{W}}, \mathbf{S}, \mathbf{Z}, \boldsymbol{\Theta}, \boldsymbol{\alpha}, \boldsymbol{\tau}) = & \prod_{m=1}^M \prod_{n=1}^N \prod_{d=1}^{D_m} \mathcal{N} \left( y_{nd}^m \mid \sum_{k=1}^K s_{dk}^m \hat{w}_{dk}^m z_{nk}, 1/\tau_d \right) \\
 & \prod_{m=1}^M \prod_{d=1}^{D_m} \prod_{k=1}^K \mathcal{N}(\hat{w}_{dk}^m \mid 0, 1/\alpha_k^m) \text{Ber}(s_{d,k}^m \mid \theta_k^m) \\
 & \prod_{n=1}^N \prod_{k=1}^K \mathcal{N}(z_{nk} \mid 0, 1) \\
 & \prod_{m=1}^M \prod_{k=1}^K \text{Beta}(\theta_k^m \mid a_0^\theta, b_0^\theta) \\
 & \prod_{m=1}^M \prod_{k=1}^K \mathcal{G}(\alpha_k^m \mid a_0^\alpha, b_0^\alpha) \\
 & \prod_{m=1}^M \prod_{d=1}^{D_m} \mathcal{G}(\tau_d^m \mid a_0^\tau, b_0^\tau).
 \end{aligned}$$

posterior distribution of unobserved data  $\mathbf{X}$ ,  $P(\mathbf{X}/\mathbf{Y})$ ,  
is approximated by  $q(\mathbf{X}) = \prod_i q(\mathbf{X}_i)$

$$q(\mathbf{Z}, \mathbf{S}, \hat{\mathbf{W}}, \boldsymbol{\alpha}, \boldsymbol{\tau}, \boldsymbol{\theta}) = q(\mathbf{Z})q(\boldsymbol{\alpha})q(\boldsymbol{\theta})q(\boldsymbol{\tau})q(\mathbf{S}, \hat{\mathbf{W}})$$



$$\mathbf{Y}^m = \mathbf{Z}\mathbf{W}^{mT} + \boldsymbol{\epsilon}^m$$

- Parameter estimation through variational Bayesian inference
- Evidence Lower Bound (ELBO)
  - the true log marginal likelihood  $\log p(\mathbf{Y})$  is lower bound by the ELBO  $\mathcal{L}(\mathbf{X})$

$$\begin{aligned}\mathcal{L}(\mathbf{X}) &= \int q(\mathbf{X}) \left( \log \frac{p(\mathbf{X}|\mathbf{Y})}{q(\mathbf{X})} + \log p(\mathbf{Y}) \right) d\mathbf{X} \\ &= \log p(\mathbf{Y}) - \text{KL}(q(\mathbf{X}) || p(\mathbf{X}|\mathbf{Y})) \\ &\leq \log p(\mathbf{Y})\end{aligned}$$

- the objective is to optimise  $\mathcal{L}(\mathbf{X})$  with respect to the distribution  $q(\mathbf{X})$



$$\mathbf{Y}^m = \mathbf{Z}\mathbf{W}^{mT} + \boldsymbol{\epsilon}^m$$

- Parameter estimation through variational Bayesian inference
- Evidence Lower Bound (ELBO)
- Iterative estimation process similar to the Expectation-Maximization (EM) algorithm
  - each unobserved variable is updated one by one considering the others

$$q(\mathbf{Z}) = \prod_{k=1}^K \prod_{n=1}^N q(z_{nk}) = \prod_{k=1}^K \prod_{n=1}^N \mathcal{N}(z_{nk} | \mu_{z_{nk}}, \sigma_{z_{nk}})$$

$$q(\hat{\mathbf{W}}, \mathbf{S}) = \prod_{m=1}^M \prod_{d=1}^{D_m} \prod_{k=1}^K q(\hat{w}_{dk}^m, s_{dk}^m) = \prod_{m=1}^M \prod_{d=1}^{D_m} \prod_{k=1}^K q(\hat{w}_{dk}^m | s_{dk}^m) q(s_{dk}^m)$$





$$\mathbf{Y}^m = \mathbf{Z}\mathbf{W}^{mT} + \boldsymbol{\epsilon}^m$$

- Parameter estimation through variational Bayesian inference
- Evidence Lower Bound (ELBO)
- Iterative estimation process similar to the Expectation-Maximization (EM) algorithm
- Iteration stop when ELBO change is small enough
- Automatically drop factors with low variance explained...



## Variance decomposition by factors for MDD dataset

→ percentage of variance explained by each factor for each data modality





- Factor 1 captures a source of variability that is present mainly in the miRNA view
- Factor 2 captures variation that is present across all data modalities but mainly in mRNA.



Feature weights by factor for each view/omic (ie a  $W^m$  column)

→ weights provide a signed score (association measure) for each feature for a given factor (below mRNA and miRNA for Factor 6, associated with Sample\_Group variable)





Identified as significant in Component 1 of supervised RGCCA (the most associated to Sample\_Group variable )



Factor values regarding known groups of samples (ie a Z row)

→ detect association between a factor and a specific variable/feature



- Separation between control and MDD patients shows association with Factor 6
- Expression of CSRNP1 gene (ENSG00000144655) is also associated with Factor 6 (and MDD status)





- Choice of **k** (number of factors)
  - inactive factors can be eliminated through a user defined threshold for explained variance
- Random initialization : no guarantee of optimal solution
  - run MOFA several times (~10 times) with different initialisations (solved in MOFA+ thanks to PCA)
  - keep the model with the highest ELBO for downstream analysis
- Missing value
  - no need for imputation, missing values are ignored in the model thanks to probabilistic modelling
- Data pre-processing
  - no need as long as indicated distributions are respected (eg. Gaussian) → to check ++




- Different views but on the same samples
- Mainly linear relationships are captured
- Assumes independence between features in the model (and samples)
- Unbalanced modalities sensibility




$$Y_{gm} = Z_g W_m^T + \epsilon_{gm}$$

- Define sample groups (batch, experiments, conditions)
- Group-wise prior applied to the Z matrix
- Stochastic variational inference framework (GPU accelerated computations)





- Additional prior on Z matrix with ARD + spike-and-slab (as for W matrix)
  - all factors are not active in each group (group-specific biological phenomenon)
  - small number of samples with active factor (sparse biological phenomenon)



- Stochastic Variational Inference
  - fast approximation of the gradient with a random subset of the data (batch)
  - gradient ascent step size adjusted at each iteration
  - efficient only when the number of samples  $\gg$  the number of features
  - additional parameters : batch size and step size (start and forgetting)

$$\mathbf{x}^{(t+1)} = \mathbf{x}^{(t)} + \rho^{(t)} \nabla F(\mathbf{x}^{(t)})$$

$$\rho^{(t)} = \frac{\tau}{(1 + \kappa t)^{3/4}}$$



- use Gaussian likelihood when possible (instead of Poisson or Bernoulli)
- use appropriate normalization to fit with available likelihoods  
*e.g. for single cell rna-seq: size factor normalization + VST*
- consider feature selection procedure before MOFA+ (*e.g. highly variable features*)
  - to limit view imbalance
  - to speedup the model
- use regression before MOFA+ to remove undesired technical sources of variation
- groups should not be defined as for a differential analysis
  - identify shared and exclusive source of variability in the data
  - larger groups → more complexity → more factors